Danish biotech bags EUR 20 million
The up-and-coming Danish biotech company Orphazyme has raised EUR 20 million. The money will be spent on a clinical study and general research in the niche field the company operates within.
BY LONNI LYNGE
The small Danish biotech company Orphazyme has hit the ground running in the new year. Late last week the company announced it had raised fresh capital in the amount of EUR 20 million in series B financing to aid the next step of its development.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Orphazyme changes Chairman in search of capital
For abonnenter
Minor biotech-success heading for patient studies
For abonnenter
Niche medicine paves the way for hard-tried Biotech
For abonnenter
